Phase I (PH I) Mad Refractory Solid Tumor Study
NCT00099606
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Neoplasms
Interventions
DRUG:
Dasatinib
Sponsor
Bristol-Myers Squibb